Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 3/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422101 | 0.91 | HTR7 (0.56) | CACNA1GFAAHHTR7HTR1AMEN1 | |
| SCHEMBL4425296 | 0.91 | HTR7 (0.57) | HTR7HTTHTR1AMEN1KMT2A | |
| SCHEMBL4419768 | 0.88 | HTR7 (0.50) | FAAHHTR7HTR1AMEN1KMT2A | |
| SCHEMBL4418590 | 0.87 | HTT (0.53) | CACNA1GFAAHSIGMAR1HTR7HTT | |
| SCHEMBL4417078 | 0.85 | CACNA1G (0.52) | CACNA1GFAAHSIGMAR1HTR7HTT | |
| SCHEMBL4415388 | 0.81 | ALDH1A1 (0.52) | HTR7HTTHTR1AMEN1KMT2A | |
| SCHEMBL4419917 | 0.81 | TSHR (0.54) | SIGMAR1HTR7HTTHTR1A | |
| SCHEMBL4430505 | 0.81 | TSHR (0.52) | HTR7HTTHTR1AKMT2A | |
| SCHEMBL4417940 | 0.80 | CACNA1G (0.56) | CACNA1GFAAHSIGMAR1HTR7HTT | |
| SCHEMBL4413980 | 0.78 | HTR1A (0.59) | HTR7HTTHTR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | disclosed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | CACNA1G 6/4885FAAH 1217/4885SIGMAR1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.